Development status of nucleic acid testing for severe acute respiratory syndrome coronavirus 2
10.3760/cma.j.cn112866-20200630-00202
- VernacularTitle:新型冠状病毒核酸检测试剂的发展现状
- Author:
Donglai LIU
1
;
Haiwei ZHOU
;
Youchun WANG
;
Sihong XU
Author Information
1. 中国食品药品检定研究院 北京 100050
- Keywords:
COVID-19;
2019 novel coronavirus;
Nucleic acid testing
- From:
Chinese Journal of Experimental and Clinical Virology
2020;34(6):582-587
- CountryChina
- Language:Chinese
-
Abstract:
As the "gold standard" for clinical diagnosis of viral infection of corona virus disease 2019 (COVID-19), nucleic acid testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) takes the heavy responsibilities in the early stage of the outbreak. The speed of response to the development, the scale of production, the convenience and reliability of clinical application, the accuracy and sensitivity of the nucleic acid testing for SARS-CoV-2 all affect the deployment and decision-making of epidemic prevention and control to varying degrees. This paper systematically investigates 138 new coronavirus nucleic acid testing reagents authorized by regulatory authorities of China and the United States, respectively, at this stage, analyzes the technical principle, degree of automation and analytical performance, and looks forward to the future development of the field of viral nucleic acid testing.
